BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pai N, Deng C, Vella SL, Castle D, Huang XF. Are there different neural mechanisms responsible for three stages of weight gain development in anti-psychotic therapy: temporally based hypothesis. Asian J Psychiatr 2012;5:315-8. [PMID: 23174439 DOI: 10.1016/j.ajp.2012.05.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 He M, Zhang Q, Deng C, Wang H, Lian J, Huang X. Hypothalamic histamine H1 receptor-AMPK signaling time-dependently mediates olanzapine-induced hyperphagia and weight gain in female rats. Psychoneuroendocrinology 2014;42:153-64. [DOI: 10.1016/j.psyneuen.2014.01.018] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 6.1] [Reference Citation Analysis]
2 Han M, Lian J, Su Y, Deng C. Cevimeline co-treatment attenuates olanzapine-induced metabolic disorders via modulating hepatic M3 muscarinic receptor: AMPKα signalling pathway in female rats. J Psychopharmacol 2021;:2698811211050549. [PMID: 34694173 DOI: 10.1177/02698811211050549] [Reference Citation Analysis]
3 He M, Deng C, Huang X. The Role of Hypothalamic H1 Receptor Antagonism in Antipsychotic-Induced Weight Gain. CNS Drugs 2013;27:423-34. [DOI: 10.1007/s40263-013-0062-1] [Cited by in Crossref: 57] [Cited by in F6Publishing: 48] [Article Influence: 6.3] [Reference Citation Analysis]
4 Liu X, Wu Z, Lian J, Hu CH, Huang XF, Deng C. Time-dependent changes and potential mechanisms of glucose-lipid metabolic disorders associated with chronic clozapine or olanzapine treatment in rats. Sci Rep 2017;7:2762. [PMID: 28584269 DOI: 10.1038/s41598-017-02884-w] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
5 Lian J, De Santis M, He M, Deng C. Risperidone-induced weight gain and reduced locomotor activity in juvenile female rats: The role of histaminergic and NPY pathways. Pharmacological Research 2015;95-96:20-6. [DOI: 10.1016/j.phrs.2015.03.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
6 He M, Zhang Q, Deng C, Wang H, Huang XF. Olanzapine-activated AMPK signaling in the dorsal vagal complex is attenuated by histamine H1 receptor agonist in female rats. Endocrinology 2014;155:4895-904. [PMID: 25264935 DOI: 10.1210/en.2014-1326] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
7 Zapata RC, Osborn O. Susceptibility of male wild type mouse strains to antipsychotic-induced weight gain. Physiol Behav 2020;220:112859. [PMID: 32156556 DOI: 10.1016/j.physbeh.2020.112859] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Galal A, El-Bakly WM, El-Kilany SS, Ali AA, El-Demerdash E. Fenofibrate ameliorates olanzapine's side effects without altering its central effect: emphasis on FGF-21-adiponectin axis. Behav Pharmacol 2021;32:615-29. [PMID: 34637209 DOI: 10.1097/FBP.0000000000000656] [Reference Citation Analysis]
9 Zhang Q, He M, Deng C, Wang H, Huang XF. Effects of olanzapine on the elevation of macrophage infiltration and pro-inflammatory cytokine expression in female rats. J Psychopharmacol 2014;28:1161-9. [PMID: 25336715 DOI: 10.1177/0269881114555250] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
10 Lian J, Huang XF, Pai N, Deng C. Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment. PLoS One 2014;9:e104160. [PMID: 25084453 DOI: 10.1371/journal.pone.0104160] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 4.8] [Reference Citation Analysis]
11 He M, Zhang Q, Deng C, Jin T, Song X, Wang H, Huang XF. Time-dependent effects of olanzapine treatment on the expression of histidine decarboxylase, H1 and H3 receptor in the rat brain: The roles in olanzapine-induced obesity. Psychoneuroendocrinology 2017;85:190-9. [PMID: 28886461 DOI: 10.1016/j.psyneuen.2017.08.022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
12 Chen J, Huang XF, Shao R, Chen C, Deng C. Molecular Mechanisms of Antipsychotic Drug-Induced Diabetes. Front Neurosci 2017;11:643. [PMID: 29209160 DOI: 10.3389/fnins.2017.00643] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 7.4] [Reference Citation Analysis]
13 Lian J, Deng C. The dosage-dependent effects of cevimeline in preventing olanzapine-induced metabolic side-effects in female rats. Pharmacol Biochem Behav 2020;191:172878. [PMID: 32112786 DOI: 10.1016/j.pbb.2020.172878] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Zhang Q, Lian J, He M, Deng C, Wang H, Huang XF. Olanzapine reduced brown adipose tissue thermogenesis and locomotor activity in female rats. Prog Neuropsychopharmacol Biol Psychiatry 2014;51:172-80. [PMID: 24548587 DOI: 10.1016/j.pnpbp.2014.02.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
15 Lian J, Huang XF, Pai N, Deng C. Betahistine ameliorates olanzapine-induced weight gain through modulation of histaminergic, NPY and AMPK pathways. Psychoneuroendocrinology 2014;48:77-86. [PMID: 24992721 DOI: 10.1016/j.psyneuen.2014.06.010] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
16 Zhang Q, He M, Deng C, Wang H, Lian J, Huang XF. Hypothalamic ghrelin signalling mediates olanzapine-induced hyperphagia and weight gain in female rats. Int J Neuropsychopharmacol 2014;17:807-18. [PMID: 24468236 DOI: 10.1017/S1461145713001697] [Cited by in Crossref: 37] [Cited by in F6Publishing: 15] [Article Influence: 4.6] [Reference Citation Analysis]
17 Deng C. Effects of antipsychotic medications on appetite, weight, and insulin resistance. Endocrinol Metab Clin North Am 2013;42:545-63. [PMID: 24011886 DOI: 10.1016/j.ecl.2013.05.006] [Cited by in Crossref: 91] [Cited by in F6Publishing: 80] [Article Influence: 11.4] [Reference Citation Analysis]
18 Babic I, Sellers D, Else PL, Nealon J, Osborne AL, Pai N, Weston-Green K. Effect of liraglutide on neural and peripheral markers of metabolic function during antipsychotic treatment in rats. J Psychopharmacol 2021;35:284-302. [PMID: 33570012 DOI: 10.1177/0269881120981377] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Ames D, Carr-Lopez SM, Gutierrez MA, Pierre JM, Rosen JA, Shakib S, Yudofsky LM. Detecting and Managing Adverse Effects of Antipsychotic Medications: Current State of Play. Psychiatr Clin North Am 2016;39:275-311. [PMID: 27216904 DOI: 10.1016/j.psc.2016.01.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
20 Nemani KL, Greene MC, Ulloa M, Vincenzi B, Copeland PM, Al-Khadari S, Henderson DC. Clozapine, Diabetes Mellitus, Cardiovascular Risk and Mortality: Results of a 21-Year Naturalistic Study in Patients with Schizophrenia and Schizoaffective Disorder. Clin Schizophr Relat Psychoses Winter;12:168-76. [PMID: 29164928 DOI: 10.3371/CSRP.KNMG.111717] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Fang H, Zhen YF, Liu XY, Xu G, Soares JC, Zhao J, Zhang XY. Association of the BDNF Val66Met polymorphism with BMI in chronic schizophrenic patients and healthy controls. Int Clin Psychopharmacol 2016;31:353-7. [PMID: 27483421 DOI: 10.1097/YIC.0000000000000142] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]